Immunotherapy in tyrosine kinase inhibitor-naïve advanced epidermal growth factor receptor-mutant non-small cell lung cancer-driving down a precarious road in driver-mutated lung cancer

Affiliations

¹ Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
² Division of Cancer Sciences, The University of Manchester, Manchester, UK.

Editorial

Rebecca Yin Tay et al. Transl Lung Cancer Res. 2018 Dec.

. 2018 Dec;7(Suppl 4):S377-S380.

doi: 10.21037/tlcr.2018.09.16.

¹ Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
² Division of Cancer Sciences, The University of Manchester, Manchester, UK.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Lack of clearly defined role for anti-programmed death-(ligand) 1 therapy in epidermal growth factor receptor mutated non-small cell lung cancer.
Lisberg A, Garon EB. Lisberg A, et al. Transl Lung Cancer Res. 2019 Apr;8(2):195-197. doi: 10.21037/tlcr.2019.02.01. Transl Lung Cancer Res. 2019. PMID: 31106131 Free PMC article. No abstract available.

A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.
Lisberg A, Cummings A, Goldman JW, Bornazyan K, Reese N, Wang T, Coluzzi P, Ledezma B, Mendenhall M, Hunt J, Wolf B, Jones B, Madrigal J, Horton J, Spiegel M, Carroll J, Gukasyan J, Williams T, Sauer L, Wells C, Hardy A, Linares P, Lim C, Ma L, Adame C, Garon EB. Lisberg A, et al. J Thorac Oncol. 2018 Aug;13(8):1138-1145. doi: 10.1016/j.jtho.2018.03.035. Epub 2018 Jun 1. J Thorac Oncol. 2018. PMID: 29874546 Free PMC article. Clinical Trial.

1. Novello S, Barlesi F, Califano R, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27:v1-27. 10.1093/annonc/mdw326 - DOI - PubMed
1. Hanna N, Johnson D, Temin S, et al. Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2017;35:3484-515. 10.1200/JCO.2017.74.6065 - DOI - PubMed
1. Ma C, Wei S, Song Y. T790M and acquired resistance of EGFR TKI: a literature review of clinical reports. J Thorac Dis 2011;3:10-8. - PMC - PubMed
1. Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer. N Engl J Med 2017;376:629-40. 10.1056/NEJMoa1612674 - DOI - PMC - PubMed
1. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med 2018;378:113-25. 10.1056/NEJMoa1713137 - DOI - PubMed